Incyte: Incyte's cancer research portfolio data will be presented in seven abstracts at the AACR's 2018 Annual Conference

by



[ad_1]

Incyte Corporation (Nasdaq: INCY) announces that seven summaries of its
A portfolio of cancer research will be presented at the
next annual conference of the American Association for Cancer Research
(AACR). The conference will be held from March 29 to April 3, 2019, in Georgia.
World Congress Center, Atlanta, Georgia.

Abstracts accepted include data from clinical studies
on Incyte anti-PD-1 monoclonal antibody, INCMGA00121,
in patients with advanced solid tumors, as well as
Preclinical characterization of the small molecule PD-L1 inhibitor program
cells, by oral administration, of the Company, and its antibody
PD-L1xCD137 bispecific.

"Data accepted for presentation during the annual conference of
AACR to illustrate our continued commitment to research
innovative approach, as we seek to offer
Innovations for cancer patients, "says Dashyant
Dhanak, Ph.D., Scientific Manager, Incyte. We are everything
particularly happy to present, for the first time in a
major medical meeting, preliminary data on our
oral program of PD-L1 inhibitors, including the main candidate,
INCB86550, has recently entered clinical trials. "

Main summaries:

clinics

Pharmacodynamic correlates in a phase 1 study of INCMGA00012, a
PD-1 antagonistic monoclonal antibody (Abstract # CT085 / 9, tests
Phase 1 clinical trials: part 3

  • Monday, April 1, 2019, 1:00 p.m. – 5:00 p.m. ET, posters section 16

Evaluation of the flat dosage strategy for INCMGA00012 in patients
with advanced tumors (Abstract # LB-268/14, most recent study
available: experimental and molecular therapy)

  • Wednesday, April 3, 2019, 8:00 a.m. – 12:00 p.m., poster section 40

preclinical

Oral presentations

New PD-1 / PD-L1 small molecule
mediating the dimerization and internalization of the PD-L1 cell surface (Abstract
# 4483, Innovative Therapy)

  • Tuesday, April 2, 2019, 3:00 p.m. – 5:00 p.m., Georgia Ballroom 3 – Georgia
    World Congress Center (Building C)

Preclinical characterization of potent and selective oral PD-L1
small molecule antagonists (Abstract # 4480, Innovative Therapy)

  • Tuesday, April 2, 2019, 3:00 p.m. – 5:00 p.m., Georgia Ballroom 3 – Georgia
    World Congress Center (Building C)

Poster presentations

An Fc-silenced IgG1 bispecific antibody (MCLA-1452)
requires PD-L1 connection to activate CD137(Abstract # 539/3, Antibody
I therapeutic

  • Sunday, March 31, 2019, 1:00 p.m. – 5:00 p.m. ET, posters section 23

An anonymous screening identified in the bispecific IgG1 CD137xPD-L1
antibody with single cell activation and binding properties (Abstract
# 541/5, therapeutic antibodies I)

  • Sunday, March 31, 2019, 1:00 p.m. – 5:00 p.m. ET, posters section 23

Characterization of human cancer xenografts in humanized line
mice (Abstract # 1050/1, humanized mice)

  • Monday, April 1, 2019, 8:00 a.m. – 10:00 p.m., poster section 4

Full information on sessions and presentations at the AACR
2019 are available at: https://www.abstractsonline.com/pp8/#!/6812.

About Incyte

Incyte Corporation is a biopharmaceutical company based in Wilmington,
in the state of Delaware, specializing in discovery,
and marketing of patented therapeutic products. for
For more information about Incyte, visit the
the company at www.incyte.com.

Follow @Incyte on Twitter at https://twitter.com/Incyte.

Forward Looking Statements

In addition to the historical information presented in this document,
the issues discussed in this press release, including
statements regarding the Company's project portfolio and its
plans for the next Annual Conference of the AACR, which
contain forecasts, estimates and other statements
Prospective. These forward-looking statements are based on expectations
of the Company and are subject to risks and uncertainties
which are likely to vary considerably the results
realities, including contingencies and risks related to
the effectiveness and safety of the Company's project portfolio,
the results of new studies and developments, the high level of
risks and uncertainties associated with drug development,
clinical trials and regulatory approval procedures, other
commercial and economic factors and the progress of competition and
technology; and other risks detailed in the manner of the period
Company reports filed with the Securities and Exchange
Commission, including the report on Form 10-K for the financial year
ended December 31, 2018. Incyte rejects any intention or obligation
to update the forward-looking statements.

1 INCMGA0012 under license from MacroGenics, Inc.
2
Development of MCLA-145 in collaboration with Merus, NV.

The text of the statement resulting from a translation must not, in any way,
be considered official. The only version of the release that does
the faith is that of the communiqué in its original language. Translation
must always be confronted with the source text, which will be a precedent.

[ad_2]

Source link